MX2023006434A - Inhibidores de quinasa y usos de los mismos. - Google Patents
Inhibidores de quinasa y usos de los mismos.Info
- Publication number
- MX2023006434A MX2023006434A MX2023006434A MX2023006434A MX2023006434A MX 2023006434 A MX2023006434 A MX 2023006434A MX 2023006434 A MX2023006434 A MX 2023006434A MX 2023006434 A MX2023006434 A MX 2023006434A MX 2023006434 A MX2023006434 A MX 2023006434A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- compounds
- methods
- kinases
- compositions
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 102000020233 phosphotransferase Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 abstract 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 abstract 1
- 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 abstract 1
- 101000635935 Homo sapiens Myosin-IIIa Proteins 0.000 abstract 1
- 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 abstract 1
- 102100026287 Misshapen-like kinase 1 Human genes 0.000 abstract 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 abstract 1
- 102100030743 Myosin-IIIa Human genes 0.000 abstract 1
- 241000772415 Neovison vison Species 0.000 abstract 1
- -1 PKG1B Proteins 0.000 abstract 1
- 101100384866 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COT1 gene Proteins 0.000 abstract 1
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan inhibidores de quinasas, composiciones farmacéuticas que comprenden tales compuestos y métodos para utilizar tales compuestos o composiciones, tales como métodos para tratar un trastorno de proliferación, tal como un cáncer o un tumor, o en algunas modalidades enfermedades o trastornos relacionados con la desrregulación de la quinasa tal como, pero no limitado a quinasas tales como MEK, COT1, FGFR4, MINK, MYO3A, PKG1B y PLK3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126364P | 2020-12-16 | 2020-12-16 | |
| PCT/US2021/063724 WO2022133040A1 (en) | 2020-12-16 | 2021-12-16 | Kinase inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006434A true MX2023006434A (es) | 2023-06-13 |
Family
ID=79425572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006434A MX2023006434A (es) | 2020-12-16 | 2021-12-16 | Inhibidores de quinasa y usos de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240083844A1 (es) |
| EP (1) | EP4263501A1 (es) |
| JP (1) | JP2023554391A (es) |
| KR (1) | KR20230144529A (es) |
| CN (1) | CN117083265A (es) |
| AU (1) | AU2021401282A1 (es) |
| CA (1) | CA3179325A1 (es) |
| MX (1) | MX2023006434A (es) |
| WO (1) | WO2022133040A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116356017A (zh) * | 2022-12-12 | 2023-06-30 | 南京腾辰生物科技有限公司 | 一种甲状腺肿瘤良恶性早期诊断标志物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1802579B1 (en) * | 2004-10-20 | 2013-11-20 | Merck Serono SA | Derivatives of 3-arylaminopyridine |
-
2021
- 2021-12-16 EP EP21841148.6A patent/EP4263501A1/en active Pending
- 2021-12-16 WO PCT/US2021/063724 patent/WO2022133040A1/en active Application Filing
- 2021-12-16 AU AU2021401282A patent/AU2021401282A1/en active Pending
- 2021-12-16 KR KR1020237024086A patent/KR20230144529A/ko unknown
- 2021-12-16 MX MX2023006434A patent/MX2023006434A/es unknown
- 2021-12-16 CN CN202180084903.0A patent/CN117083265A/zh active Pending
- 2021-12-16 US US18/266,793 patent/US20240083844A1/en active Pending
- 2021-12-16 JP JP2023536389A patent/JP2023554391A/ja active Pending
- 2021-12-16 CA CA3179325A patent/CA3179325A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3179325A1 (en) | 2022-06-23 |
| KR20230144529A (ko) | 2023-10-16 |
| EP4263501A1 (en) | 2023-10-25 |
| JP2023554391A (ja) | 2023-12-27 |
| CN117083265A (zh) | 2023-11-17 |
| AU2021401282A1 (en) | 2023-07-13 |
| US20240083844A1 (en) | 2024-03-14 |
| WO2022133040A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| PH12020551760A1 (en) | Pyridazinones as parp7 inhibitors | |
| CR20220584A (es) | Inhibidores de kras tricíclicos fusionados | |
| MX2021009246A (es) | Inmunomoduladores, composiciones y metodos de los mismos. | |
| PH12018500587A1 (en) | Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer | |
| UA99833C2 (en) | Pyrimidinyl pyridazinone derivates | |
| JOP20200315A1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| UA95934C2 (ru) | Производные пиридиазинона для лечения опухолей | |
| PH12014501355B1 (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
| EA201792529A1 (ru) | Ингибиторы тирозинкиназы | |
| EA201891268A1 (ru) | Соединения, которые можно применять в качестве ингибиторов киназы | |
| NZ718728A (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| MX2019012176A (es) | Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral. | |
| PH12020551853A1 (en) | Axl kinase inhibitors and use of the same | |
| PH12020551390A1 (en) | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| PH12020551495A1 (en) | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations | |
| MX2021012705A (es) | Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa. | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
| MX2023006434A (es) | Inhibidores de quinasa y usos de los mismos. | |
| MX2021011925A (es) | Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano. |